Statin Selection in Patients With Pre-Diabetes: Case Considerations

Slides:

Advertisements

Similar presentations

What's New in Basal Insulin for Diabetes

Advertisements

Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.

The Latest Lipid Guidelines:

Diabetic Dyslipidemia in Practice

Updates and Perspectives in Diabetic Dyslipidemia

Statin Selection in the Elderly

Optimizing Statin Therapy

Making the Case for Metabolic Surgery in Patients With Obesity and T2DM.

An Endocrinology Clinic in Dyslipidemia

Patient Case 1 Peggy Peggy Interactive Case Question.

Special Consideration in Insulin Therapy

Statin Selection Aimed to Reduce New-Onset DM Risk:

Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.

Tailoring Statin Therapy in Women

SGLT2 Inhibitors: What Do the Data Mean for My Patients?

Epilepsy Treatment Across the Spectrum

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

What Comes Second?.

American Heart Association Scientific Sessions

Obesity and Dyslipidemia: How Would You Treat?

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Statins and the Elderly Patient

Statin Selection in Special Patient Populations: A Case Challenge

SGLT2 Inhibitors in the Modern Era: Why and Where?

Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.

Understanding Statin Metabolism

What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?

Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

Statin Class in Session

Diabetes Increases Risk of CVD

Assessing the State of Statin Therapy

Improving Management of Type 2 Diabetes in Hispanic/Latino Patients

New Pathways in Lipid Care

What's New in Dyslipidemia?

Statins and Glucose Metabolism: Are All Agents Alike?

Figure 5 Risk factor control in the intensive treatment group

Statin Class in Session

PCP View: ACC/AHA Guidelines: Role of Moderate Intensity Statins

A Journal Club on Lipid Management:

Overview. 5 Things You Need to Know About Statin Selection in Patients With HIV Infection.

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Statins and HIV:.

New LDL-C Lipid Targets

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?

Simplifying Insulin Delivery for Better Patient Outcomes in T2D

Novel Approaches to T1D Management

Lipid Clinic Challenge

Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?

Oral Combination Therapy for T2D

Diabetes Pandemic. The Economics of Managing Patients With Diabetes and Coronary Artery Disease: A Payer Perspective.

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

Statins, Obesity, and Hyperlipidemia

Liraglutide Shows CV Benefit: Clinical Perspectives on the LEADER Trial

Glucose Management and Statin Therapy

Add-On Therapy to Insulin in T1DM Management

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Clinical Challenges and Updates in Managing Seizure Clusters

New Lipid-Lowering Guidelines

Statins and Glucose Metabolism: An Endocrinology Perspective

AMD Therapy: Where Are We Now and Where Are We Going?

Glucose Management and Statin Therapy

Statin Therapy in Patients With Insulin Resistance

New Advances in Hybrid Closed-Loop Control of Insulin Therapy

Fresh perspectives ON BASAL Insulins in diabetes care

Motor Fluctuations in PD

Presentation transcript:

Statin Selection in Patients With Pre-Diabetes: Case Considerations

Goals

Questions: Statins and the Risk of New Onset T2D

Pitavastatin and HbA1c (%) 7 Clinical Trials

Certain Statins Increase the Risk of New Onset T2D

Metabolic Syndrome

Pitavastatin and New-Onset Diabetes 15 Clinical Trials

Ticking Clock Phenomenon

JUPITER: Rosuvastatin Therapy and T2D Risk

Choosing One’s Risk

Case 1: Patient Details

Case 1: Treatment Considerations

Case 2: Patient Details

Case 2: Treatment Considerations

Abbreviations